Aakaar Medical Technologies Ltd. Reports H1 FY27 Profit Turnaround

Aakaar Medical Technologies Ltd. reported a profit after tax of INR 3.54 crore for H1 FY27, reversing a loss of INR 0.78 crore a year earlier, while revenue from operations rose 72.6% year-on-year to INR 43.72 crore. The half-year performance marks a return to operating and net profitability based on the company's Q2 FY27 investor presentation.

What did Aakaar Medical Technologies Ltd. report for H1 FY27?

Aakaar Medical Technologies Ltd. reported sales of INR 43.72 crore for the half year ended September 30, 2026, compared with INR 25.33 crore in the corresponding period a year earlier. Revenue was INR 43.99 crore, against INR 25.62 crore in H1 FY26, according to the reported earnings results.

The company reported net income of INR 3.54 crore, compared with a net loss of INR 0.78 crore in the prior-year period. Basic and diluted earnings per share from continuing operations were INR 2.50 each, compared with a loss per share of INR 0.63 in H1 FY26.

The investor presentation separately described revenue from operations as INR 43.72 crore, up 72.6% from INR 25.32 crore. The small difference between reported total revenue and revenue from operations reflects the different line items presented in the disclosed financial information.

How did Aakaar Medical Technologies Ltd. return to profitability?

Aakaar Medical Technologies Ltd. returned to profitability as EBITDA turned positive at INR 5.43 crore in H1 FY27, compared with an EBITDA loss of INR 0.23 crore a year earlier. Its EBITDA margin was 12.42%, versus a negative 0.91% in H1 FY26, according to the investor presentation.

The improvement in EBITDA was followed by a shift in profit after tax to INR 3.54 crore. The reported figures show that the increase in revenue was accompanied by a recovery in operating profitability during the half year, rather than only a rise in the top line.

The presentation also reported Aakaar own-brand sales revenue of INR 14.90 crore in H1 FY27. For context, own-brand sales were INR 22.40 crore for the full FY26. The available disclosure does not provide a separate half-year comparison for own-brand sales or a management explanation for the change.

What is the financial background to the H1 FY27 result?

Aakaar Medical Technologies Ltd. had reported growth in the preceding full year as well. For the year ended March 31, 2026, sales were INR 66.90 crore, compared with INR 61.60 crore in the prior year, while revenue rose to INR 67.70 crore from INR 61.80 crore.

Net income for FY26 was INR 6.60 crore, up from INR 6.00 crore in FY25. The H1 FY27 result therefore follows a year in which the company had already recorded annual profitability, although the comparable H1 FY26 period had shown operating and net losses.

The latest half-year performance should be read alongside the distinction between annual and interim financial periods. H1 FY27 covers the six months ended September 30, 2026, while FY26 covers the twelve months ended March 31, 2026. The disclosures do not provide a full segment-wise breakdown of the half-year revenue increase in the supplied material.

What does the result mean for investors and operations?

The result means Aakaar Medical Technologies Ltd. has reported higher revenue alongside positive EBITDA and profit after tax for H1 FY27. For investors, the key disclosed improvement is the movement from a negative EBITDA margin to a 12.42% margin, coupled with positive earnings per share of INR 2.50.

No share-price movement, valuation impact, dividend decision, or market reaction is included in the available material. The disclosed financial data therefore supports an assessment of reported operating and earnings performance, but not a conclusion on how the stock market responded to the announcement.

The company has not published an earnings-call transcript for this quarter, according to the investor-presentation material. As a result, the available figures represent reported presentation data and do not include management guidance, a separately disclosed capex amount, or a capex plan for H1 FY27.

Conclusion

Aakaar Medical Technologies Ltd. reported a material H1 FY27 improvement, with revenue from operations rising to INR 43.72 crore and EBITDA, profit after tax, and earnings per share all turning positive against losses in the comparable period. The figures indicate that the revenue increase was accompanied by an improvement in operating margin.

The next disclosed result reference is an earnings release for Q2 FY27 dated October 24, while the available information does not set out management guidance or a capex plan. Investors will need subsequent filings, financial statements, and any future company communication to assess whether the reported margin and profitability improvement is sustained.